Loading...
Loading...
Immunomedics, Inc.
, a biopharmaceutical company primarily focused on the
development of monoclonal antibody-based products for the targeted treatment
of cancer, autoimmune and other serious diseases, today reported that multiple
cycles of therapy with the Company's pancreatic cancer therapeutic,
clivatuzumab tetraxetan labeled with yttrium-90 (^90Y), in combination with
low-dose gemcitabine, produced a median overall survival (OS) of more than 5
months in patients with metastatic pancreatic cancer who had received at least
2 prior treatments.
Results from the Phase Ib clinical trial were updated by Dr. William A.
Wegener, Senior Vice President, Clinical Research, in an oral presentation at
the 26^th Annual Congress of the European Association of Nuclear Medicine in
Lyon, France.
Despite a difficult-to-treat patient population with relapsing disease, a
partial response in 53 CT-assessable patients was reported at the Congress. In
addition, median OS for patients with partial response or stable disease as
best response was longer than those with disease progression (131 days vs. 66
days, respectively).
"Based on these encouraging results, which have to be confirmed with a Phase
III clinical trial, we are proceeding with our plan to initiate such trial
with clivatuzumab in this late-stage disease setting," commented Cynthia L.
Sullivan, President and Chief Executive Officer. "We are preparing to open
this pivotal study before the end of 2013 or the beginning of 2014," Ms.
Sullivan added.
With the acronym PANCRIT, which stands for PANcreatic Cancer
RadioImmunotherapy Trial, the Phase III study will be a double-blind,
randomized trial of ^90Y-clivatuzumab tetraxetan with low-dose gemcitabine,
versus placebo and low-dose gemcitabine in metastatic pancreatic cancer
patients who have progressed on at least 2 prior therapies, 1 of which must be
a gemcitabine-containing regimen.
Target enrollment for this multicenter, international trial is 440 patients. A
majority of these patients will be recruited at clinical sites across the
U.S., with additional sites in Canada, Europe and Israel participating.
Patients will be randomized 2 to 1 to the treatment arm.
Primary endpoint of PANCRIT will be overall survival, with objective response,
progression-free survival and clinical benefit such as quality of life serving
as secondary outcome measures.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in